Radioembolization

Dan Brown, MD
Dan Brown, MD, shows case examples demonstrating timing of Y-90 therapy and personalizing therapy to the patient's biology.
liver
Patients with hepatocellular carcinoma (HCC) and gross vascular invasion (GVI) may have improved overall survival (OS) after being treated with dual modality radiation with external beam radiation therapy (EBRT) and transarterial radioembolization (TARE). Researchers reported their findings in the… Read More
liver
Transarterial radioembolization with yttrium-90 (TARE-Y90) may be worth considering as an adjunctive therapy for pediatric patients with unresectable hepatic malignancies, according to a study published in Pediatric Blood Cancer. “TARE-Y90 of unresectable primary liver malignancy is both… Read More
IV drips
Transarterial radioembolization with yttrium-90 (TARE-Y90) of unresectable primary liver malignancy demonstrates an anticancer effect and could be used as adjunctive therapy in pediatric patients with unresectable hepatic malignancies. A new study published in Pediatric Blood & Cancer found… Read More
LIver Cancer spot
A nomogram including 6 pre-Y90 radioembolization (RAE) parameters predicted overall survival (OS) post-RAE, according to a study published in Clinical Colorectal Cancer. A total of 103 patients with colorectal cancer liver metastases treated with RAE from September 15, 2009 to March 21, 2017 were… Read More
HCC liver
A new study found that Y90 radioembolization with glass microspheres given at a boosted dose in patients with large hepatocellular carcinomas (HCCs) may show favorable tumor response. The results, which were published in the Journal of Vascular and Interventional Radiology, also found that the… Read More
HCC cells
A new study that looked at outcomes of surgical resection after yttrium-90 (Y90) transarterial radioembolization (TARE) in patients with hepatocellular carcinoma found that TARE can serve as a safe bridge to resection. The results were published in the Journal of Vascular and Interventional… Read More
liver
The mutational status and histopathologic grade of patients with chemorefractory colorectal liver metastases (CRLM) may predict survival after Y90 radioembolization therapy, according to a study published in Oncotarget. Patients with wild-type mutation status along with a well-differentiated tumor… Read More
HCC liver
Using 3D voxel-based dosimetry in patients with hepatocellular carcinoma (HCC) treated by yttrium-90 (90Y) resin microspheres radioembolization, a new study determined that complete  tumor targeting and 90Y dose to tumor are independent factors associated with clinical outcomes. The results were… Read More
Dr. Gandhi
Interventional radiologists who are interested in performing Y90 should be aware of clinical red flags including bilirubin trends, potent radiosensitizers, prior biliary intervention, and the presence of ascites, according to a presentation by Ripal Gandhi, MD, FSVM, FSIR at the Symposium on… Read More